Published in Am J Pathol on October 01, 2010
Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc (2011) 1.10
Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol (2011) 1.02
Modelling headache and migraine and its pharmacological manipulation. Br J Pharmacol (2014) 0.86
Neurovascular contributions to migraine: Moving beyond vasodilation. Neuroscience (2016) 0.80
Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective function in dopamine-based neurodegeneration developed in two parkinsonian models. Dis Model Mech (2016) 0.75
Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition. Int J Mol Sci (2016) 0.75
Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med (2000) 3.71
Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev (2000) 3.24
Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev (2009) 3.22
Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun (1989) 3.03
Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci (2003) 2.94
Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev (2006) 2.30
NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol (2005) 1.58
Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun (1990) 1.52
Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol (1999) 1.45
Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology (1994) 1.43
Alkaline phosphatase activity and localization during the murine hair cycle. Br J Dermatol (1994) 1.34
Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology (1991) 1.30
Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol (2003) 1.20
Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci U S A (1995) 1.18
Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: A link to neurogenic skin disorders. Brain Behav Immun (1999) 1.18
Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front Neuroendocrinol (1995) 1.16
Agonists of proteinase-activated receptor-2 stimulate upregulation of intercellular cell adhesion molecule-1 in primary human keratinocytes via activation of NF-kappa B. J Invest Dermatol (2005) 1.16
Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappaB in human dermal microvascular endothelial cells. J Invest Dermatol (2002) 1.12
VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol (1999) 1.09
VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J (2004) 1.08
Mast cell involvement in murine hair growth. Dev Biol (1994) 1.06
Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol (2006) 1.05
Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci U S A (2002) 1.02
Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology (1999) 1.01
Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience (1993) 1.00
Towards the development of a simplified long-term organ culture method for human scalp skin and its appendages under serum-free conditions. Exp Dermatol (2007) 0.99
PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways. Curr Protein Pept Sci (2002) 0.98
PACAP in immunity and inflammation. Ann N Y Acad Sci (2003) 0.97
Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol (1999) 0.97
Pituitary adenylate cyclase-activating polypeptide: a novel, long-lasting, endothelium-independent vasorelaxant. Eur J Pharmacol (1991) 0.97
Neuroimmune interactions in allergic skin diseases. Curr Opin Allergy Clin Immunol (2007) 0.97
Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol (2001) 0.96
Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J Neuroendocrinol (1996) 0.92
The vasorelaxant effect of pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in isolated rat basilar arteries is partially mediated by activation of nitrergic neurons. Regul Pept (2002) 0.92
Pituitary adenylate cyclase activating polypeptide is a potent vasodilator and oedema potentiator in rabbit skin in vivo. Br J Pharmacol (1992) 0.88
Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: expression of PACAP-38 is increased in patients with psoriasis. Regul Pept (1999) 0.87
Pituitary adenylate cyclase-activating polypeptide induces hyperthermia in the rat. Neuropharmacology (2000) 0.87
Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br J Dermatol (1999) 0.86
Pituitary adenylate cyclase activating peptide (PACAP) in guinea-pig lung: distribution and dilatory effects. Regul Pept (1991) 0.86
VIP and PACAP inhibit activation induced apoptosis in T lymphocytes. Ann N Y Acad Sci (2000) 0.84
PKA-Bad-14-3-3 and Akt-Bad-14-3-3 signaling pathways are involved in the protective effects of PACAP against ischemia/reperfusion-induced cardiomyocyte apoptosis. Regul Pept (2007) 0.83
Mast cells and their role in urticaria. J Am Acad Dermatol (1991) 0.83
VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. J Immunol (1999) 0.83
Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. J Neuroimmunol (1999) 0.82
Inhibitory effect of PACAP-38 on acute neurogenic and non-neurogenic inflammatory processes in the rat. Peptides (2007) 0.82
Vessel tone and remodeling. Nat Med (2006) 0.82
Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res (1998) 0.82
Substance P is diminished and vasoactive intestinal peptide is augmented in psoriatic lesions and these peptides exert disparate effects on the proliferation of cultured human keratinocytes. J Invest Dermatol (1992) 0.81
PACAP-induced plasma extravasation in rat skin. Regul Pept (1997) 0.79
Sex-related differences and thyroid hormone regulation of vasoactive intestinal peptide gene expression in the rat brain and pituitary. Brain Res (1990) 0.78
Cardiovascular and respiratory actions of pituitary adenylate cyclase-activating polypeptides. Regul Pept (1992) 0.78
Mast cells contribute to PACAP-induced dermal oedema in mice. Regul Pept (1999) 0.78
Stem cell factor influences neuro-immune interactions: the response of mast cells to pituitary adenylate cyclase activating polypeptide is altered by stem cell factor. Regul Pept (1999) 0.77
Physiopathology of urticaria. Eur J Dermatol (1999) 0.76
Specific monoclonal antibodies neutralize the action of PACAP 1-27 or PACAP 1-38 on intestinal muscle strips in vitro. Regul Pept (1995) 0.76
Vascular effects and cyclic AMP production produced by VIP, PHM, PHV, PACAP-27, PACAP-38, and NPY on rabbit ovarian artery. Peptides (1996) 0.76
Creation of a selective antagonist and agonist of the rat VPAC(1) receptor using a combinatorial approach with vasoactive intestinal peptide 6-23 as template. Mol Pharmacol (2000) 0.76
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet (2009) 9.32
The neurobiology of itch. Nat Rev Neurosci (2006) 3.25
Molecular principles of hair follicle induction and morphogenesis. Bioessays (2005) 3.08
Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci (2003) 2.94
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature (2010) 2.85
Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. J Dtsch Dermatol Ges (2011) 2.82
Separate peripheral pathways for pruritus in man. J Neurophysiol (2008) 2.64
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
Alopecia areata. N Engl J Med (2012) 2.56
The hair follicle as a dynamic miniorgan. Curr Biol (2009) 2.52
Exploring the "hair growth-wound healing connection": anagen phase promotes wound re-epithelialization. J Invest Dermatol (2010) 2.48
Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain (2005) 2.42
Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev (2005) 2.42
IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol (2006) 2.39
Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease. Clin Chim Acta (2010) 2.31
Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev (2006) 2.30
IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev (2006) 2.29
Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. FASEB J (2005) 2.23
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes (2007) 2.19
Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain (2003) 2.18
Reciprocal requirements for EDA/EDAR/NF-kappaB and Wnt/beta-catenin signaling pathways in hair follicle induction. Dev Cell (2009) 2.17
Fibulin-5 mutations link inherited neuropathies, age-related macular degeneration and hyperelastic skin. Brain (2011) 2.15
Cdc42 controls progenitor cell differentiation and beta-catenin turnover in skin. Genes Dev (2006) 2.10
Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest (2007) 2.09
Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol (2006) 2.08
IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. Nat Med (2007) 2.00
Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest (2006) 1.90
Hair follicle pigmentation. J Invest Dermatol (2005) 1.84
Functional assessment of pancreatic beta-cell area in humans. Diabetes (2009) 1.82
Naevus lentiginosus linearis: A distinct skin disorder. Acta Derm Venereol (2010) 1.80
Partial pancreatectomy in adult humans does not provoke beta-cell regeneration. Diabetes (2007) 1.78
The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. Sci Signal (2011) 1.75
Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol (2006) 1.72
Retracted A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control. EMBO J (2005) 1.72
Neuroimmunology of stress: skin takes center stage. J Invest Dermatol (2006) 1.72
The interleukin-15/interleukin-15 receptor system as a model for juxtacrine and reverse signaling. Bioessays (2006) 1.70
Evaluation of protease-activated receptor 2 in murine models of arthritis. Arthritis Rheum (2007) 1.70
Epidermal nerve fibers modulate keratinocyte growth via neuropeptide signaling in an innervated skin model. J Invest Dermatol (2013) 1.67
NF-kappaB transmits Eda A1/EdaR signalling to activate Shh and cyclin D1 expression, and controls post-initiation hair placode down growth. Development (2006) 1.66
"Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis. J Invest Dermatol (2008) 1.64
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes (2004) 1.62
High spontaneous activity of C-nociceptors in painful polyneuropathy. Pain (2012) 1.62
RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol (2011) 1.60
Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A (2007) 1.58
Neuronal plasticity of the "brain-skin connection": stress-triggered up-regulation of neuropeptides in dorsal root ganglia and skin via nerve growth factor-dependent pathways. J Mol Med (Berl) (2007) 1.58
Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest (2007) 1.56
Cylindroma as tumor of hair follicle origin. J Invest Dermatol (2006) 1.56
Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts. J Invest Dermatol (2009) 1.55
Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol (2006) 1.53
Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol (2004) 1.52
Protein phosphatase 2A mediates resensitization of the neurokinin 1 receptor. Am J Physiol Cell Physiol (2011) 1.51
Mast cells are required for normal healing of skin wounds in mice. FASEB J (2006) 1.50
Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). Neurosci Lett (2008) 1.50
Circadian clock genes contribute to the regulation of hair follicle cycling. PLoS Genet (2009) 1.49
Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol (2008) 1.47
Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol (2007) 1.46
Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med (2009) 1.45
Itch. Lancet (2003) 1.45
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab (2003) 1.45
Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol (2013) 1.44
Thyrotropin-releasing hormone selectively stimulates human hair follicle pigmentation. J Invest Dermatol (2011) 1.43
Immunophenotyping of the human bulge region: the quest to define useful in situ markers for human epithelial hair follicle stem cells and their niche. Exp Dermatol (2008) 1.43
Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res (2006) 1.42
Sustained partial remission of metastatic pancreatic cancer following systemic chemotherapy with gemcitabine and oxaliplatin plus adjunctive treatment with mistletoe extract. Onkologie (2010) 1.41
13C-methionine breath test detects distinct hepatic mitochondrial dysfunction in HIV-infected patients with normal serum lactate. J Acquir Immune Defic Syndr (2005) 1.40
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology (2003) 1.37
Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology (2006) 1.36
Molecular biology of hair morphogenesis: development and cycling. J Exp Zool B Mol Dev Evol (2003) 1.36
Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood (2005) 1.34
Perioperative intravenous lidocaine has preventive effects on postoperative pain and morphine consumption after major abdominal surgery. Anesth Analg (2004) 1.34
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care (2010) 1.33
Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. J Invest Dermatol (2006) 1.33
Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem (2005) 1.32
Plasticity and cytokinetic dynamics of the hair follicle mesenchyme: implications for hair growth control. J Invest Dermatol (2003) 1.32
Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med (2004) 1.30
Bradykinin is a potent pruritogen in atopic dermatitis: a switch from pain to itch. Pain (2006) 1.29
Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol (2010) 1.28
Endosomal endothelin-converting enzyme-1: a regulator of beta-arrestin-dependent ERK signaling. J Biol Chem (2009) 1.27
A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J Pathol (2005) 1.27
The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest (2013) 1.27
Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept (2002) 1.27
Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc (2011) 1.27
Migration of melanoblasts into the developing murine hair follicle is accompanied by transient c-Kit expression. J Histochem Cytochem (2002) 1.26
Ichthyosis, follicular atrophoderma, and hypotrichosis caused by mutations in ST14 is associated with impaired profilaggrin processing. J Invest Dermatol (2008) 1.26
UVB radiation generates sunburn pain and affects skin by activating epidermal TRPV4 ion channels and triggering endothelin-1 signaling. Proc Natl Acad Sci U S A (2013) 1.26
Electrically evoked itch in humans. Pain (2005) 1.25
Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol (2004) 1.25
Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J Invest Dermatol (2007) 1.25
Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. J Invest Dermatol (2004) 1.24